News & Sentiment
$15M Investment to Launch High Tech Ice Manufacturing Facility in Oak Park - 50 New Jobs
Motor City Ice repurposes former 30,000-square-foot Forgotten Harvest building into a fully automated ice production facility serving Metro Detroit. DETROIT, Oct. 27, 2026 /PRNewswire/ -- A group of three established Metro Detroit business families has invested more than $15 million to...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
340 articles
📰
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while...
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while...
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while...
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while...
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get...
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get...
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with...
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with...
Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...
Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) Director James Foster sold 24,042 shares of the company’s...
📰
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply...
📰
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply...
Intuitive Surgical (NASDAQ:ISRG) VP Fredrik Widman Sells 4,047 Shares of Stock
Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) VP Fredrik Widman sold 4,047 shares of the firm’s stock in a transaction on...
Intuitive Surgical (NASDAQ:ISRG) Director Gary Guthart Sells 20,095 Shares of Company Stock
Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) Director Gary Guthart sold 20,095 shares of the stock in a transaction dated Friday,...